Search

Displaying results 4621 - 4630 of 10000 in total
  1. Drug

    cryopreserved human liver cells

    go.drugbank.com/drugs/DB05852
    Experimental

    The Company's technology is centered on the isolation, expansion, and cryopreservation of liver cells (human hepatocytes) obtained from organ donor livers that are not suitable for whole organ transplantation

  2. Drug

    ONT-093

    go.drugbank.com/drugs/DB14069
    Experimental

    In pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations with no effect on paclitaxel pharmacokinetics. … ONT-093 is an orally bioavailable inhibitor of P-glycoprotein (P-gp).

  3. Drug

    Fontolizumab

    go.drugbank.com/drugs/DB05111
    Investigational

    Fontolizumab (marketed under the trade name HuZAF™) is a humanized monoclonal antibody which is used as an immunosuppressive drug to treat Crohn's disease.

  4. Drug

    AG-702

    go.drugbank.com/drugs/DB05836
    Experimental

    HSPs are present in all cells in all life forms from bacteria to mammals, and their structure and function are similar across these diverse life forms.

  5. Drug

    Terevalefim

    go.drugbank.com/drugs/DB16397
    Investigational

    Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).

  6. Drug

    2-octyl cyanoacrylate

    go.drugbank.com/drugs/DB12040
    Investigational

    Dermabond has been investigated for the basic science of Wound Healing.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Arylacenamide

    go.drugbank.com/drugs/DB05792
    Experimental

    Arylacenamide (SR31747) is a peripheral [sigma] ligand that binds four proteins in human cells, i.e. SRBP-1, [sigma]-2, HSI and its relative SRBP-2.

  8. Drug

    AV608

    go.drugbank.com/drugs/DB05072
    Investigational

    AV608 is a NK-1 antagonist. It is developed for the treatment of Social anxiety disorder (SAD), irritable bowel syndrome (IBS) and overactive bladder (OAB).

  9. Drug

    Nirogacestat

    go.drugbank.com/drugs/DB12005
    ApprovedInvestigational

    Desmoid tumors are typically characterized by aberrant activation in Notch signaling. … It was previously granted breakthrough therapy, fast track, and orphan drug designations for the treatment of desmoid tumors, and the final approval was based on positive results obtained in the Phase

  10. Drug

    Pozelimab

    go.drugbank.com/drugs/DB15218
    ApprovedInvestigational

    [A261115] The loss of CD55 can therefore induce complement hyperactivation, causing the unwanted formation of membrane-attacking complex and resulting in paroxysmal nocturnal hemoglobinuria and complement-mediated … autoimmune hemolysis that are often observed in CHAPLE disease.